Immune thrombocytopenia (ITP): vizsgálatok itt: Lengyelország
11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- Where
- Gdansk, Lodz, Skorzewo, Slupsk
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Sanofi
See details and how to joinNCT07007962 · EU 2025-522070-36-00 - 1/2. fázisTaking peopleA Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- Where
- Cracow, Katowice, Skorzewo, Torun
- Életkor
- 18 év to 64 év
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06721013 · EU 2024-518502-40-00 - 3. fázisTaking peopleA Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Katowice, Lodz, Warsaw
- Életkor
- 18 év and over
- People
- 171 worldwide
- Run by
- Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00 - 1. fázisTaking peoplePhase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
- Where
- Warsaw
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00 - 3. fázisTaking peopleA Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Katowice, Lodz, Warsaw
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00 - 2/3. fázisTaking peopleA Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
- Where
- Cracow, Gdansk, Lodz, Lublin, Warsaw
- Életkor
- 12 év to 17 év
- People
- 24 worldwide
- Run by
- argenx
See details and how to joinNCT07194850 · EU 2025-521055-23-00 - 2. fázisTaking peopleSafety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
- Where
- Katowice, Skorzewo
- Életkor
- 18 év to 80 év
- People
- 30 worldwide
- Run by
- Nuvig Therapeutics, Inc.
See details and how to joinNCT07095127 · EU 2024-520359-26-00 - 1. fázisTaking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Warsaw
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - 1. fázisCsak meghívásosPhase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Where
- Warsaw
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06723106 - 1. fázisTaking peopleA Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911
- Where
- Warsaw
- Életkor
- 18 év to 64 év
- People
- 76
- Run by
- Qilu Pharmaceutical Co. Ltd.
See details and how to join2025-523355-59-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Where
- Bydgoszcz, Katowice, Lodz, Lublin, Nowy Sacz, Torun
- Életkor
- 18 év and over
- People
- 69 worldwide
- Run by
- argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00